Bicara Therapeutics (NASDAQ:BCAX) Issues Quarterly Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) issued its earnings results on Monday. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22), FiscalAI reports.

Bicara Therapeutics Price Performance

Shares of BCAX stock opened at $8.65 on Monday. The firm has a market cap of $572.40 million, a P/E ratio of -2.79 and a beta of -0.33. Bicara Therapeutics has a 1-year low of $7.87 and a 1-year high of $30.99. The firm’s 50-day simple moving average is $18.16 and its 200-day simple moving average is $20.95.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a research report on Thursday, September 10th. Citigroup reissued a “market outperform” rating on shares of Bicara Therapeutics in a research report on Friday, August 21st. Wedbush cut their price target on Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating for the company in a report on Thursday, October 29th. BMO Capital Markets began coverage on Bicara Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price objective on the stock. Finally, HSBC lowered Bicara Therapeutics to an “equal weight” rating in a research note on Tuesday, September 22nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $30.91.

Insider Buying and Selling at Bicara Therapeutics

In related news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total value of $400,750.00. Following the transaction, the chief executive officer owned 181,641 shares in the company, valued at approximately $4,159,578.90. This trade represents a 8.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is currently owned by company insiders.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-?), a signaling protein that can contribute to tumor growth and immune suppression.